Poor
Not Aligned
Patient Risk:
Low
Summary
Only the formulation claim (“branded fixed-dose combination”) is supported by the provided label section (11 DESCRIPTION). All pricing/cost-related claims are unsupported by the provided label text and therefore do not align with the supplied prescribing information.
Category Scores
Accurate Statements
Duetact is a branded fixed-dose combination.
11 DESCRIPTION states DUETACT is available as tablets containing fixed strengths of pioglitazone (30 mg) and glimepiride (2 mg or 4 mg).
Unsupported Statements
Duetact (pioglitazone/glimepiride) pricing depends on the dose.
The provided label section (11 DESCRIPTION) does not discuss pricing or dose-related cost.
Duetact pricing depends on whether the patient pays cash or uses insurance.
The provided label section (11 DESCRIPTION) contains no information about cash vs. insurance pricing.
Duetact pricing depends on the pharmacy.
The provided label section (11 DESCRIPTION) does not mention pharmacy-specific pricing.
Out-of-pocket cost for Duetact varies based on the insurance plan and formulary tier.
The provided label section (11 DESCRIPTION) does not discuss formularies, tiers, or out-of-pocket cost determinants.
Out-of-pocket cost for Duetact varies based on whether the plan requires prior authorization or step therapy.
The provided label section (11 DESCRIPTION) does not mention prior authorization, step therapy, or associated cost variability.
Out-of-pocket cost for Duetact varies based on deductibles and copay/coinsurance rules.
The provided label section (11 DESCRIPTION) does not address deductibles, copays, coinsurance, or out-of-pocket cost rules.
Pharmacy pricing differences can affect out-of-pocket cost for the same drug.
The provided label section (11 DESCRIPTION) does not address pharmacy pricing differences or their impact on patient cost.
Manufacturer assistance or pharmacy discount programs can affect Duetact out-of-pocket cost when available.
The provided label section (11 DESCRIPTION) does not mention manufacturer assistance, discount programs, or impacts on out-of-pocket cost.
Contradictions
Important Omissions
No omission assessed for FDA-label elements because the evaluated claims are primarily about pricing/cost and the only label-supported element provided is the fixed-dose formulation description.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern pricing/cost information rather than dosing, contraindications, boxed warnings, or safety/efficacy directions; however, they are not supported by the provided labeling text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (pricing/out-of-pocket/cost determinants) are unsupported by the provided FDA label section (11 DESCRIPTION).
Suggested Improvement
Remove or revise pricing/cost/cash-vs-insurance/formulary/prior-authorization/step-therapy/coupon/assistance statements unless supported by the actual approved labeling text provided.